Tech Transfer eNews Blog

MGFB licenses novel cancer therapeutic platform from Mayo Clinic


By Jesse Schwartz
Published: November 16th, 2022

MGFB, a subsidiary of biotherapeutics developer FairWinds Bio (FWB), has signed a patent license agreement with Mayo Clinic to develop and commercialize experimental cancer vaccine therapeutics.

Based on a novel platform developed by Mayo Clinic professor Richard Vile and several of his colleagues, the therapeutics deliver a range of tumor associated antigens to produce strong T cell responses. Preclinical studies have demonstrated durable responses in a melanoma study in mice.

Through the license agreement, MGFB plans to advance multiple programs from the lab to the clinic, particularly in areas of disease where current therapeutic options are limited.

“We are very excited to collaborate with Mayo Clinic on this approach to treating solid tumors,” says Ajit Gill, CEO of MGFB. “Our objective is to develop the most therapeutically effective constructs with the hope of providing patients better therapeutic alternatives.”

Professor Richard Vile comments, “I look forward to working with the MGFB team to advance these therapeutic vaccines to help the many patients who need better treatment options than are currently available.”

Source: Cision

Posted under: Tech Transfer e-News